There has been so much bad news on the Alzheimer’s front, it was refreshing to read that an experimental treatment from Eli Lilly & Company helped patients.  Granted, it was a small trial of 272 people with mild Alzheimer’s disease, but results show that donanemab met the primary goal of the study, slowing the decline in memory and the ability to perform activities of daily living by 32% over an 18-month period.  Lilly is so excited about the results that it started enrolling another 500 subjects for a new study to confirm the findings.

Recommended Posts